標(biāo)題: Titlebook: Cancer Immunology; Bench to Bedside Imm Nima Rezaei Book 2021Latest edition Springer Nature Switzerland AG 2021 Cancer immunotherapy.Transl [打印本頁(yè)] 作者: 拖累 時(shí)間: 2025-3-21 16:19
書(shū)目名稱Cancer Immunology影響因子(影響力)
作者: Daily-Value 時(shí)間: 2025-3-21 20:34
Strategies to Target Tumor Immunosuppression,osuppression, are pivotal for potent antitumor immunity..This chapter provides an overview of the main immune tolerance and immunosuppression mechanisms within the tumor microenvironment and discusses effective immunotherapeutic interventions that target homing and activity of immune effector cells 作者: Etymology 時(shí)間: 2025-3-22 03:09 作者: Respond 時(shí)間: 2025-3-22 07:29 作者: Cabinet 時(shí)間: 2025-3-22 10:01
Combination of Chemotherapy and Cytokine Therapy in Treatment of Cancers,okines have demonstrated potential for therapeutic synergy. For example, it is possible to potentiate the development of specific immune response by reducing the dose of conventional chemotherapy (e.g., cyclophosphamide, gemcitabine, paclitaxel, and doxorubicin). This chapter provides currently evid作者: 背帶 時(shí)間: 2025-3-22 14:33 作者: 背帶 時(shí)間: 2025-3-22 20:41 作者: FLASK 時(shí)間: 2025-3-22 23:33
Adoptive T-Cell Therapy: Optimizing Chemokine Receptor-Mediated Homing of T-Cells in Cancer Immunotoited to improve T-cell homing to tumors. The possibility of developing novel strategies to bring more T-cell effectors into tumors will surely enhance the efficacy of adoptive T-cell therapies. These strategies, also in combination with current checkpoint blockade, hold great promise for the future作者: Embolic-Stroke 時(shí)間: 2025-3-23 01:36
Toll-Like Receptor Pathway and Its Targeting in Treatment of Cancers,ancer progression. Hence, more investigations are required to discover proper therapeutic approaches for cancer. Multiple trials have been designed recently to detect the therapeutic role of TLR agonist in addition to chemotherapy. Also, the role of TLR agonist as a vaccine adjuvant for different ty作者: Migratory 時(shí)間: 2025-3-23 08:59 作者: Collar 時(shí)間: 2025-3-23 09:50 作者: MITE 時(shí)間: 2025-3-23 13:55 作者: 玷污 時(shí)間: 2025-3-23 19:24
R. Vanholder,R. Dell’Aquila,S. Ringoirosuppression, are pivotal for potent antitumor immunity..This chapter provides an overview of the main immune tolerance and immunosuppression mechanisms within the tumor microenvironment and discusses effective immunotherapeutic interventions that target homing and activity of immune effector cells 作者: Glucose 時(shí)間: 2025-3-23 23:55 作者: CRUDE 時(shí)間: 2025-3-24 05:46
K. Okumura,F. Viallefond,M. Viton,W. Riceessing investigations are made to enhance the immune responses against tumor-associated antigens, which are presented by cancer vaccines. Vaccine delivery methods are of great importance for better antigen presentation to the immune system. Developing prime-boost vaccines showed successful results i作者: 寵愛(ài) 時(shí)間: 2025-3-24 07:43 作者: 搏斗 時(shí)間: 2025-3-24 12:12
New Aspects of Mesozoic Biodiversitylls, contributing to cancer immunoediting. Type I IFNs are approved for the treatment of a number of cancers, including melanoma, renal cell carcinoma, and Kaposi’s sarcoma. However, currently the biggest challenge in the therapeutic use of type I IFNs, as well as other cytokines, is the toxic side 作者: 立即 時(shí)間: 2025-3-24 17:29
https://doi.org/10.1007/978-3-322-99112-6nt of cancer and their current limitations will be reviewed. Finally, as to stimulate more research on the mechanisms that govern the interactions between γδ T-Cells and tumors, this chapter will end by discussing future perspectives in γδ T-cell-based cancer immunotherapy.作者: Senescent 時(shí)間: 2025-3-24 21:42
New Aspects of Nuclear Dynamicsoited to improve T-cell homing to tumors. The possibility of developing novel strategies to bring more T-cell effectors into tumors will surely enhance the efficacy of adoptive T-cell therapies. These strategies, also in combination with current checkpoint blockade, hold great promise for the future作者: 掃興 時(shí)間: 2025-3-25 01:41
New Aspects of Quantum Electrodynamicsancer progression. Hence, more investigations are required to discover proper therapeutic approaches for cancer. Multiple trials have been designed recently to detect the therapeutic role of TLR agonist in addition to chemotherapy. Also, the role of TLR agonist as a vaccine adjuvant for different ty作者: canonical 時(shí)間: 2025-3-25 03:21 作者: 顧客 時(shí)間: 2025-3-25 10:49
https://doi.org/10.1007/978-3-642-49747-6nt aim for TAMs research is to repolarize TAMs from tumor promotive macrophages to tumor suppressive macrophages, meaning to establish new strategies efficient for reeducating TAMs to be cytotoxic in tumors.作者: 魔鬼在游行 時(shí)間: 2025-3-25 15:09
immunotherapy for organ-specific tumors. .Cancer Immunology: Bench to Bedside Immunotherapy of Cancers. .will be of special value to clinical immunologists, hematologists, and oncologists...?.978-3-030-50289-8978-3-030-50287-4作者: BUOY 時(shí)間: 2025-3-25 16:02 作者: 情感 時(shí)間: 2025-3-25 22:38
978-3-030-50289-8Springer Nature Switzerland AG 2021作者: 確定無(wú)疑 時(shí)間: 2025-3-26 00:18 作者: periodontitis 時(shí)間: 2025-3-26 04:42
Criteria for Steps to Higher Energies, Contemporary standpoints in understanding mechanisms of innate and adaptive immunity are the basis for development and improvement of immunotherapy approaches. Despite the theoretical rationale and experimental basis of antitumor cytotoxicity of induced lymphocytes, adoptive immunotherapy with lymp作者: Encumber 時(shí)間: 2025-3-26 10:57
Play Fighting and Real Fighting,vailable to improve management of these diseases..Cancer treatments are not effective in all patients in the same way. This could happen because there is a phase in which the tumor acquires irreversibility characteristics that no longer allow the physiological defense system to attack and eliminate 作者: Entropion 時(shí)間: 2025-3-26 13:17 作者: 返老還童 時(shí)間: 2025-3-26 19:45 作者: Bumptious 時(shí)間: 2025-3-26 23:01 作者: 教育學(xué) 時(shí)間: 2025-3-27 04:11
K. Okumura,F. Viallefond,M. Viton,W. Rice. Advances in designing tumor-selective viral and nonviral vectors allow for more efficient gene delivery. Clinically approved gene therapies can be classified into several approaches such as sensitizing tumors to chemotherapies, targeting angiogenesis, and restoring tumor suppressing functions. Adj作者: Spartan 時(shí)間: 2025-3-27 06:50
J.F. Bonaparte,C.L. Schultz,M.B. Soareshe treatment of solid tumors. Myeloablative, reduced-intensity, or non-myeloablative “conditioning” serves to eliminate or reduce the number of malignant cells, create “space” in the hematopoietic compartment for the expansion of transplanted hematopoietic cells, and provide a hematopoietic environm作者: hegemony 時(shí)間: 2025-3-27 09:32
Sankar Chatterjee,Christopher Scoteset it offers a potential readily available family donor to almost every patient. The application of h-HCT has particularly benefited minority populations who frequently do not find a suitable unrelated donor. Different options exist utilizing either T cell depletion strategies or T cell-replete graft作者: MEAN 時(shí)間: 2025-3-27 16:57
New Aspects of Mesozoic Biodiversityective immune response against cancer cells and to revert the immunosuppressive microenvironment are currently being carried out. Cytokines such as interleukin (IL)-2, IL-7, IL-12, IL-15, IL-18, granulocyte macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF),作者: reception 時(shí)間: 2025-3-27 21:49
New Aspects of Mesozoic Biodiversitycle to infect a host cell. Besides viral interference, since their discovery, IFNs have been further implicated in different processes linked to immunity and cancer. The family of IFNs has been divided into three categories according to biological properties and signaling pathways: type I IFNs (cons作者: monochromatic 時(shí)間: 2025-3-28 01:02 作者: 人工制品 時(shí)間: 2025-3-28 02:35
https://doi.org/10.1007/978-3-322-99112-6em attractive targets for cancer immunotherapy, namely, their major histocompatibility complex (MHC)-unrestricted recognition of tumors, potent cytotoxicity, and abundant production of interferon-γ (IFN-γ) and tumor necrosis factor (TNF). Moreover, seminal work with mice genetically deficient for γδ作者: inculpate 時(shí)間: 2025-3-28 09:49
New Aspects of Nuclear Dynamicsreat majority of patients. During the past few decades, several strategies for enhancing its efficacy have been developed and introduced into the clinic. These include different maneuvers such as ex vivo expansion of autologous lymphocytes isolated from tumor, manipulating tumor-infiltrating lymphoc作者: 有效 時(shí)間: 2025-3-28 11:58 作者: ACME 時(shí)間: 2025-3-28 14:47
New Aspects of Quantum Electrodynamicsune responses. In particular, most of the studies have been centered on TLRs that play a pivotal role in tumor biology. TLR activation acts as a double-edged sword with both pro- and antitumor responses. Certain TLRs activate PI3K/Akt pathway, leading to tumor progression. In contrast, few TLRs are 作者: 推遲 時(shí)間: 2025-3-28 21:37 作者: saturated-fat 時(shí)間: 2025-3-28 23:50 作者: 寬度 時(shí)間: 2025-3-29 05:37
https://doi.org/10.1007/978-3-642-49747-6 characteristics of these macrophages got elucidated only recently. These macrophages, called tumor-associated macrophages (TAMs), can enhance tumor invasion, migration, and angiogenesis, and human TAMs have been characterized by the expression of CD163 and CD68 on plasma membrane. Similar to altern作者: MIRTH 時(shí)間: 2025-3-29 09:47 作者: 旁觀者 時(shí)間: 2025-3-29 15:06 作者: 賠償 時(shí)間: 2025-3-29 17:21 作者: Pastry 時(shí)間: 2025-3-29 21:28 作者: Glutinous 時(shí)間: 2025-3-30 01:11 作者: COM 時(shí)間: 2025-3-30 04:17 作者: 尊嚴(yán) 時(shí)間: 2025-3-30 10:31
Strategies to Target Tumor Immunosuppression,ile antigen-specific immune responses play a crucial role in tumor rejection, the tumor hampers these immune responses by creating an immunosuppressive microenvironment. Recently, major progress has been achieved in the field of cancer immunotherapy, and several groundbreaking clinical trials demons作者: 上坡 時(shí)間: 2025-3-30 13:32 作者: CRACY 時(shí)間: 2025-3-30 19:19
Gene Therapy and Genetic Vaccines,. Advances in designing tumor-selective viral and nonviral vectors allow for more efficient gene delivery. Clinically approved gene therapies can be classified into several approaches such as sensitizing tumors to chemotherapies, targeting angiogenesis, and restoring tumor suppressing functions. Adj作者: 柔軟 時(shí)間: 2025-3-30 22:57 作者: IRATE 時(shí)間: 2025-3-31 04:27
Recent Advances in Haploidentical Hematopoietic Cell Transplantation for Pediatric Hematologic Malit it offers a potential readily available family donor to almost every patient. The application of h-HCT has particularly benefited minority populations who frequently do not find a suitable unrelated donor. Different options exist utilizing either T cell depletion strategies or T cell-replete graft作者: cruise 時(shí)間: 2025-3-31 09:05 作者: 事先無(wú)準(zhǔn)備 時(shí)間: 2025-3-31 11:58
Type I Interferons: History and Perspectives as Immunotherapeutic Agents Against Cancer,cle to infect a host cell. Besides viral interference, since their discovery, IFNs have been further implicated in different processes linked to immunity and cancer. The family of IFNs has been divided into three categories according to biological properties and signaling pathways: type I IFNs (cons作者: 愉快嗎 時(shí)間: 2025-3-31 16:29
T-Cell Immunotherapy: From Synthetic Biology to Clinical Practice, their ability to alter the tumor microenvironment. Polyclonal T-cell populations, T-cell clones, and T-cells engineered to express chimeric antigen receptors (CARs) have all been expanded in various ways outside the body and then reintroduced for therapeutic effect. From naturally occurring T-cell 作者: 溺愛(ài) 時(shí)間: 2025-3-31 18:59 作者: Servile 時(shí)間: 2025-3-31 21:49 作者: Delude 時(shí)間: 2025-4-1 03:58 作者: 眨眼 時(shí)間: 2025-4-1 08:25
Toll-Like Receptor Pathway and Its Targeting in Treatment of Cancers,une responses. In particular, most of the studies have been centered on TLRs that play a pivotal role in tumor biology. TLR activation acts as a double-edged sword with both pro- and antitumor responses. Certain TLRs activate PI3K/Akt pathway, leading to tumor progression. In contrast, few TLRs are 作者: 無(wú)目標(biāo) 時(shí)間: 2025-4-1 12:52
Recent Advances in the Use of NK Cells Against Cancer,or cells, as well as how tumors try to subvert this attack, has led to many new ideas about how to make NK cell immunotherapy more effective. Advances in both technology and methodology have made it possible to generate large numbers of NK cells to utilize in either autologous or allogeneic NK cell 作者: Hippocampus 時(shí)間: 2025-4-1 14:48
Dendritic Cell Vaccines for Cancer Therapy: Fundamentals and Clinical Trials,s have figured as effective agents of customized medicine. Dendritic cells (DCs) are key cells to trigger an effective antitumor response, being the only antigen-presenting cells (APCs) able to prime na?ve T lymphocytes for tumor antigens. Therefore, several approaches have been proposed to use thes作者: macular-edema 時(shí)間: 2025-4-1 19:17 作者: Onerous 時(shí)間: 2025-4-1 22:52 作者: indifferent 時(shí)間: 2025-4-2 04:39 作者: 拍下盜公款 時(shí)間: 2025-4-2 09:38 作者: 是突襲 時(shí)間: 2025-4-2 12:22
